Trial Profile
A 12 Month, Multi-center, Randomized, Open-label Non-inferiority Study Comparing Safety and Efficacy of Concentration-controlled Everolimus With Low Dose Tacrolimus to Mycophenolate Mofetil With Standard Dose Tacrolimus in de Novo Renal Transplant Recipients.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Jul 2018
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Mycophenolate mofetil; Tacrolimus
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Sponsors Novartis
- 06 Jun 2018 Results of post hoc analysis assessing everolimus trough levels around the onset of related adverse events and treatment discontinuation presented at the 2018 American Transplant Congress
- 06 Jun 2018 Results (n=965) evaluating the effect of everolimus dosing schedules on efficacy outcomes from 2 studies (US92 and TRANSFORM) presented at the 2018 American Transplant Congress
- 03 May 2017 Results of a post-hoc analysis investigating the influence of delayed graft function on renal function and duration of dialysis, presented at the 2017 American Transplant Congress